Global Albumin Market Charts a Path to 6% CAGR Growth by 2026
The development of albumin-based nanoparticles for drug delivery, high demand for albumin in R&D activities & clinical trials, rising production of immunoglobulin, growing plasma collection, increased preference for recombinant albumin in drug delivery, rising awareness about the benefits of albumin, growing usage of albumin as blood volumizer in a condition of shocks & burns, and rise in non-therapeutic applications of albumin as a multifunctional excipient are some of the key factors driving the global albumin market.
Albumin is the most abundant circulating protein in plasma, accounting for more than half of the total protein in human plasma. Albumin has received a lot of attention as a protein carrier for drug delivery. They are utilized in oncology, diabetes, hepatitis C, hypovolemia, and rheumatoid arthritis, among other things.
Albumin market is being driven by rising
demand for albumin in R&D and clinical trials
Albumin-based
therapeutic medicines are particularly useful in the treatment and diagnosis of
cancer, inflammatory, metabolic, and viral illnesses. Albumin is drawing the
attention of researchers, pharmaceutical, and biotech businesses due to the
commercial success of products that use it as a medication carrier and the
current clinical trials.
Albumin-Based Nanoparticles Provide a
Potential Drug Delivery System for Cancer Treatment
Albumin is a versatile biomaterial that
can be used to create nanoparticles. The effectiveness of albumin-based
administration is based on its ability to improve tumor targeting and
accumulation. Furthermore, albumin has the ability to connect to specific
receptors that are overexpressed on cancer cells, enhancing nanoparticle
binding and internalization.
Explore Detailed Insights on Albumin Market @ https://www.globenewswire.com/en/news-release/2022/11/07/2549866/0/en/Global-Albumin-Market-is-estimated-to-grow-at-a-decent-CAGR-of-6-by-2026-Growing-preference-for-Recombinant-Albumin-in-Drug-Delivery.html
Growing Recombinant Albumin vs.
Serum-Based Albumin for Drug Delivery
The
use of serum-derived albumin has decreased as regulatory guidelines have
spurred the need for animal-free solutions. The past hazards connected with
human serum albumin have been eliminated with the availability of recombinant
albumin. It also offers a reasonably easy alternative to standard formulation
procedures and a cost-effective, single solution to multiple stability
difficulties.
The Potential Role of Human Serum Albumin
in Covid-19 Patients Drives Albumin Market Growth
Albumin
has been shown to improve the ratio of arterial partial pressure of
oxygen/fraction of inspired oxygen in patients with acute respiratory distress
syndrome as soon as 24 hours after treatment and with an effect that lasts at
least seven days. Furthermore, researchers that evaluated the clinical
characteristics of Covid-19 patients reported that low serum albumin on
presentation is associated with a greater prevalence of adverse outcomes such
as kidney injury, heart injury, and higher mortality, among others.
Albumin Market: Key Market Challenges
The primary factors inhibiting albumin
market growth include severe government restrictions, restricted reimbursement,
a rising shift toward serum-free solutions, and adverse effects associated with
albumin use.
North America has the largest market
share, but APAC is expected to grow the fastest in the albumin market.
North
America has the biggest market share of albumin. This is primarily due to
increased demand for albumin-based R&D activities, the availability of
advanced and robust healthcare infrastructure, increased demand for albumin in
different non-therapeutic applications, and the presence of market important
players in the region.
Albumin Market Competitive Landscape Analysis
The presence of established market companies such as Baxter
International Inc., China Biologic Products Inc, Grifols S.A., Apotex Corp.,
and InVitria, among others, characterizes the worldwide albumin market.
Companies are pursuing both organic and inorganic growth strategies in order to expand their market share in the global albumin market.
To gain a larger market share, all competitors in the global market are
implementing organic and inorganic growth methods such as collaborations,
acquisitions, and expansions. As an example,
- In April 2022, Apotex Corp. announced the release of its Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane in the United States.
- In January 2022, Bio Products Laboratory (BPL), announced that the National Medical Products Administration (NMPA) for China has granted BPL a license to market ALBUMINEX® 25% product to China.
Get Detailed
Insights on Albumin Market with TOC and a Sample Report PDF @ https://meditechinsights.com/global-albumin-market/
Comments
Post a Comment